Durable coronavirus stock Moderna (NASDAQ: MRNA) rose by over 3.5% in price on Monday, nearly quadrupling the percentage gain of the S&P 500 index on the day. The move followed news that the company racked up yet another approval from a healthcare authority for a new booster version of its Spikevax coronavirus vaccine. Late Friday after market hours, Moderna announced that the second of its two bivalent booster vaccines targeting the coronavirus had been authorized for use in Canada.